Celgene Corporation (CELG) is Initiated by Stifel to Buy, Price Target at $138

Celgene Corporation (CELG) was Initiated by Stifel to “Buy” and the brokerage firm has set the Price Target at $138. Stifel advised their investors in a research report released on Jul 15, 2016.

Many Wall Street Analysts have commented on Celgene Corporation. Company shares were Reiterated by Sun Trust Rbsn Humphrey on Apr 29, 2016 to “Buy”, Firm has raised the Price Target to $ 147 from a previous price target of $145 .

On the company’s financial health, Celgene Corporation reported $1.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.27. The company had revenue of $2511.60 million for the quarter, compared to analysts expectations of $2577.08 million. The company’s revenue was up 20.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.07 EPS.

Celgene Corporation closed down -1.65 points or -1.60% at $101.76 with 41,63,585 shares getting traded on Wednesday. Post opening the session at $104.07, the shares hit an intraday low of $101.63 and an intraday high of $104.23 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

In a different news, on Jun 22, 2016, Robert J Hugin (director officer ) sold 75,000 shares at $100.16 per share price. According to the SEC, on Apr 5, 2016, Gilla Kaplan (director) sold 15,967 shares at $101.84 per share price. On Mar 7, 2016, Michael W Bonney (director) purchased 2,000 shares at $103.01 per share price, according to the Form-4 filing with the securities and exchange commission.

Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Celgene Corporation

Leave a Reply

Celgene Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Celgene Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.